Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2016 | TGR-1202 in CLL and non-Hodgkin lymphoma

Howard Burris • 3 Jun 2016
ASCO 2016
Chronic Lymphocytic Leukemia Non-Hodgkin Lymphoma Duvelisib Idelalisib Umbralisib

Howard Burris, MD from Sarah Cannon, Nashville, TN discusses TGR-1202 for chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). TGR-1202 is a PI3K delta inhibitor and Dr Burris discusses how it may be the third compound in this area that will be used in the clinic next to idelalisib and IPI-145. TGR-1202 is well tolerated and is used as a single agent and in combination.
Recorded at the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL.

More from Howard Burris

1:13
bb2121: a promising outlook for the future of multiple myeloma
Howard Burris • 14 Jun 2018
2:46
The use and benefits of liquid biopsy
Howard Burris • 3 Jun 2016

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
1:48
Novel immunotherapy approaches in lymphoma: CAR-T cells, bispecifics & sequencing
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals